medwireNews: EULAR has released provisional recommendations for the management of rheumatic diseases during the COVID-19 pandemic.
Presenting the highlights of the recommendations at the EULAR 2020 E-Congress, Robert Landewé (Amsterdam Rheumatology Center, the Netherlands) said there is no evidence to suggest that patients with rheumatic and musculoskeletal diseases (RMDs) have a higher risk for SARS-CoV-2 infection or a worse COVID-19 disease course than the general population.
He emphasized that “rheumatologists should definitely be involved” in discussions on the management of RMDs in patients with COVID-19, and highlighted potential issues with availability of rheumatology drugs due to their overuse for treating patients with COVID-19.
Landewé stressed that the currently available evidence for managing RMD patients in the context of COVID-19 is “extremely sparse” and that the recommendations would be updated when new evidence becomes available.
The provisional recommendations have been published in the Annals of the Rheumatic Diseases.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group